Precision BioSciences Inc. Form 8-K Summary
Business Context and Reporting Period
Precision BioSciences Inc. (DTIL), a Delaware corporation, filed this Current Report on Form 8-K on February 6, 2020, covering events occurring on February 3, 2020. The company is an emerging growth company with its principal executive offices in Durham, North Carolina.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The report focuses exclusively on a corporate governance agreement.
Material Changes
The Company entered into Amendment No. 2 to its Amended and Restated Investors' Rights Agreement. Key changes include:
- Expiration of Registration Rights: A Holder's rights to request registration of securities now expire when the Holder can sell all shares in a three-month period without registration or volume limitations under Rule 144, or when the Holder is no longer an Affiliate of the Company.
- Definition of Required Holders: The definition was amended to require the written consent or affirmative vote of holders of a majority of the Registrable Securities then outstanding.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a procedural filing regarding the amendment of an existing contractual agreement.
Investor Verification Checklist
- Review Exhibit 10.1 (Amendment No. 2) for the complete legal text of the amended Investors' Rights Agreement.
- Verify the current status of the Company's "Affiliate" status for major shareholders to determine if registration rights have expired.
- Confirm the impact of the "Required Holders" definition change on future corporate actions requiring shareholder consent.